uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Heparin-induced thrombocytopenia: recommendations for optimal use of recombinant hirudin.
Department of Transfusion Medicine, Greifswald University, Germany.
2000 (English)In: BioDrugs, ISSN 1173-8804, E-ISSN 1179-190X, Vol. 14, no 2, 109-25 p.Article in journal (Refereed) Published
Abstract [en]

Recombinant hirudins have a definite role in the treatment of patients with heparin-induced thrombocytopenia (HIT). The most important adverse effects are haemorrhages and the induction of antihirudin antibodies. Major haemorrhages were not significantly increased in patients with HIT compared with a historical control group, but prospective data comparing hirudin and heparinoids such as danaparoid are lacking. The definition of the optimal method for monitoring and the availability of an antidote for hirudin would probably increase safety with this drug. To date, haemofiltration using high-flux filter systems is the only way to remove an overdosage of hirudin from the circulation. In patients with renal impairment requiring hirudin treatment, it therefore seems safer to start with a low dose that is subsequently adjusted according to the activated partial prothromboplastin time or ecarin clotting time. Even in special circumstances, such as cardiopulmonary bypass or dialysis, hirudins can be applied successfully if care is taken to monitor their effects meticulously. There are many other indications in which hirudins have shown feasibility (e.g. acute coronary syndromes) but available data preclude definite conclusions.

Place, publisher, year, edition, pages
2000. Vol. 14, no 2, 109-25 p.
National Category
Clinical Medicine
Identifiers
URN: urn:nbn:se:uu:diva-161354PubMedID: 18034563OAI: oai:DiVA.org:uu-161354DiVA: diva2:456042
Available from: 2011-11-11 Created: 2011-11-11 Last updated: 2017-12-08

Open Access in DiVA

No full text

PubMed

Authority records BETA

Lubenow, Norbert

Search in DiVA

By author/editor
Lubenow, Norbert
In the same journal
BioDrugs
Clinical Medicine

Search outside of DiVA

GoogleGoogle Scholar

pubmed
urn-nbn

Altmetric score

pubmed
urn-nbn
Total: 347 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf